Product Name: CEA Antibody [CCM661]
Species Reactivity: Human
Tested Applications: Flow, IF, IHC
Applications: Flow Cytometry: 0.5-1 ug/million cellsIF: 1-2 ug/mlIHC (FFPE): 0.5-1 ug/ml for 30 min at RT (1)Prediluted format : incubate for 30 min at RT (2)The concentration stated for each application is a general starting point. Variations in protocols, secondaries and substrates may require the CEA antibody to be titered up or down for optimal performance.1. Staining of formalin-fixed tissues requires boiling tissue sections in 10mM Citrate Buffer, pH 6.0, for 10-20 min followed by cooling at RT for 20 minutes.2. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.
User Note: Optimal dilutions for each application to be determined by the researcher
Predicted Molecular Weight:
Immunogen: Human full-length recombinant protein was used as the immunogen for this CEA antibody.
Host Species: Mouse
Purification: Protein G affinity chromatography
Physical State: Liquid
CAS NO.: 1243583-85-8
Product: MG 149
Buffer: PBS with 0.1 mg/ml BSA and 0.05% sodium azide
Concentration: 0.2 mg/mL
Storage Conditions: Aliquot and Store at -20C. Avoid freez-thaw cycles.
Clonality: Monoclonal
Conjugate: Unconjugated
Alternate Names: CEACAM5 Antibody : CEA, CD66e, CEA, Carcinoembryonic antigen-related cell adhesion molecule 5, Carcinoembryonic antigen
Accession NO.:
Protein Ino:
Official Symbol: CEACAM5
Geneid: 1048
Background: CEA is synthesized during development in the fetal gut and is re-expressed in increased amounts in intestinal carcinomas and several other tumors. CEA is not found in benign glands, stroma, or malignant prostatic cells. Antibody to CEA is useful in detecting early foci of gastric carcinoma and in distinguishing pulmonary adenocarcinomas (60-70% are CEA+) from pleural mesotheliomas (rarely or weakly CEA+).
PubMed ID:http://aac.asm.org/content/35/10/1989.abstract
